🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

Recruitingn/aAges 18 Years - anyAllSir Mortimer B. Davis - Jewish General Hospital
NCT05530096 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Confirmed MM diagnosis * Transplant eligible patients in a first remission * Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed) * Availability of deidentified patient's demographic and clinical follow up data * Receiving standard of care treatment * Able to provide informed consent Exclusion Criteria: * Failure to meet inclusion criteria
💊

What it tests

  • Standard of care
📍

Where

1 site
Jewish General Hospital
Montreal, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy